We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Kite Pharma, Inc. is scheduled to report second-quarter 2016 results on Aug 8, after the market closes. The company, which started trading from Jun 2014, posted a positive earnings surprise in the last quarter. Let's see how things are shaping up for this announcement.
Factors at Play
Kite Pharma, a development-stage biopharmaceutical company, is looking to transform the paradigm of treating cancer which involves using the body’s immune system to recognize and destroy cancer cells. The company uses its engineered autologous cell therapy (eACT) to genetically modify T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T-cells are designed to recognize and destroy cancer cells.
Kite Pharma’s revenues comprise the amortization of deferred collaboration revenues related to the $60 million upfront payment received under its collaboration agreement with Amgen, Inc. (AMGN - Free Report) in the first quarter of 2015.
With no approved products in its portfolio, investor focus will be primarily on the company’s cash burn and pipeline updates.
At the time of releasing first quarter results, Kite had guided towards 2016 net cash burn of $235 - $250 million and net loss of $295 - $310 million.
KTE-C19, Kite’s lead pipeline candidate, is currently in the pivotal phase of a phase I-II study (ZUMA-1) in patients with refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). All these are types of aggressive non-Hodgkin’s lymphoma (NHL). If the study generates positive data (interim results expected in the second half of 2016), Kite intends to seek accelerated FDA approval for the treatment of patients with refractory DLBCL, PMBCL and TFL by the end of 2016 and EU approval in 2017. If all goes well, KTE-C19 could be launched as early as 2017.
Kite is also conducting a phase II study (ZUMA-2) on KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL) and two additional pivotal studies (phase I/II) for acute lymphoblastic leukemia (ALL) - ZUMA-3 for adult ALL and ZUMA-4 for pediatric ALL, with results from all these studies due in 2017.
Kite plans to move KTE-C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients.
Apart from updates on KTE-C19, investor focus will remain on the company’s progress with its collaboration agreements with several companies including Amgen.
Surprise History
Kite’s performance over the last four quarters is mixed with the company surpassing expectations in two quarters and missing in the other two. Overall, the company posted an average earnings surprise of +4.80% over the past four quarters.
Our proven model does not conclusively show that Kite Pharma is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Kite Pharma is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are a loss of $1.28 per share.
Zacks Rank: Kite Pharma carries a Zacks Rank #3. Kite Pharma’s Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks you may want to consider as our model shows that they have the right combination of elements to post a beat this quarter.
The Earnings ESP for Ionis Pharmaceuticals, Inc. (IONS - Free Report) is +10.71% and it carries a Zacks Rank #2. The company will release second-quarter results on Aug 9.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +300.00% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Kite Pharma, Inc. is scheduled to report second-quarter 2016 results on Aug 8, after the market closes. The company, which started trading from Jun 2014, posted a positive earnings surprise in the last quarter. Let's see how things are shaping up for this announcement.
Factors at Play
Kite Pharma, a development-stage biopharmaceutical company, is looking to transform the paradigm of treating cancer which involves using the body’s immune system to recognize and destroy cancer cells. The company uses its engineered autologous cell therapy (eACT) to genetically modify T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T-cells are designed to recognize and destroy cancer cells.
Kite Pharma’s revenues comprise the amortization of deferred collaboration revenues related to the $60 million upfront payment received under its collaboration agreement with Amgen, Inc. (AMGN - Free Report) in the first quarter of 2015.
With no approved products in its portfolio, investor focus will be primarily on the company’s cash burn and pipeline updates.
At the time of releasing first quarter results, Kite had guided towards 2016 net cash burn of $235 - $250 million and net loss of $295 - $310 million.
KTE-C19, Kite’s lead pipeline candidate, is currently in the pivotal phase of a phase I-II study (ZUMA-1) in patients with refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). All these are types of aggressive non-Hodgkin’s lymphoma (NHL). If the study generates positive data (interim results expected in the second half of 2016), Kite intends to seek accelerated FDA approval for the treatment of patients with refractory DLBCL, PMBCL and TFL by the end of 2016 and EU approval in 2017. If all goes well, KTE-C19 could be launched as early as 2017.
Kite is also conducting a phase II study (ZUMA-2) on KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL) and two additional pivotal studies (phase I/II) for acute lymphoblastic leukemia (ALL) - ZUMA-3 for adult ALL and ZUMA-4 for pediatric ALL, with results from all these studies due in 2017.
Kite plans to move KTE-C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients.
Apart from updates on KTE-C19, investor focus will remain on the company’s progress with its collaboration agreements with several companies including Amgen.
Surprise History
Kite’s performance over the last four quarters is mixed with the company surpassing expectations in two quarters and missing in the other two. Overall, the company posted an average earnings surprise of +4.80% over the past four quarters.
KITE PHARMA INC Price and EPS Surprise
KITE PHARMA INC Price and EPS Surprise | KITE PHARMA INC Quote
Earnings Whispers?
Our proven model does not conclusively show that Kite Pharma is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to be able to beat earnings. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Kite Pharma is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are a loss of $1.28 per share.
Zacks Rank: Kite Pharma carries a Zacks Rank #3. Kite Pharma’s Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks you may want to consider as our model shows that they have the right combination of elements to post a beat this quarter.
The Earnings ESP for Ionis Pharmaceuticals, Inc. (IONS - Free Report) is +10.71% and it carries a Zacks Rank #2. The company will release second-quarter results on Aug 9.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +300.00% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>